Dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with newly diagnosed systemic AL amyloidosis for whom bortezomib in combination with cyclophosphamide and dexamethasone is the suitable therapy for the individual patient
Hint of considerable added benefit
Project details
- Project no.
- A25-40
- Commission
- Commission awarded on 28.02.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-40_en
Connected Projects
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed